United States Securities and Exchange Commission
                    Washington, D. C. 20549

                          FORM 10-QSB

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                     EXCHANGE ACT OF 1934

            For the quarterly period June 30, 2005

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

               For the transition period from to

                 Commission File No. 000-32393

                          eGene, Inc.
(Exact Name of Small Business Issuer as Specified in its Charter)

       NEVADA                                        87-0645507
       ------                                        ----------
(State or Other Jurisdiction of                 (I.R.S. Employer I.D. No.)
 incorporation or organization)


              17841 Fitch, Irvine, California 92614
             (Address of Principal Executive Offices)

            Issuer's Telephone Number: (949) 250-8686

Check whether the Registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter Period that the issuer was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

         APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
           PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                        Not applicable.

Check whether the Registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court. Yes   No
                                                 ---  ---

             APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the Registrant's classes
of common stock, as of the latest practicable date.

The number of our outstanding shares of common stock as of June 30, 2005, was
13,439,351 (actual); however, assuming all stockholders of BioCal Technology,
Inc., a California corporation ("BioCal"), who did not perfect dissenters'
rights in the merger of our wholly-owned subsidiary that was formed for the
sole purpose of merging with and into BioCal submit their BioCal shares for
exchange under that Agreement and Plan of Merger and by which BioCal became a
wholly-owned subsidiary of ours, then there will be 15,624,188 outstanding
shares.

Transitional Small Business Disclosure Format (Check One): Yes X No

eGene, Inc.


                       Table of Contents
                                                                         Page

PART I    FINANCIAL INFORMATION

Item 1.   Financial Statements
          Condensed Consolidated Balance Sheet as of June 30, 2005

          Condensed Consolidated Statements of Operations for the
          Three and Six Months Ended June 30, 2005 and 2004

          Condensed Consolidated Statements of Cash Flows for the
          Three and Six Months Ended June 30, 2005 and 2004

          Notes to Unaudited Condensed Consolidated Financial Statements

Item 2.   Management's Discussion and Analysis of Financial Condition and
          Results of Operations

Item 3.   Controls and Procedures

PART II   OTHER INFORMATION

Item 1.   Legal Proceedings

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds

Item 3.   Defaults upon Senior Securities

Item 4.   Submission of Matters to a Vote of Security Holders

Item 5.   Other Information

Item 6.   Exhibits

SIGNATURES
 EX-31.1 302 Certification of Ming S. Liu
 EX-32   906 Certification



                PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

The Financial Statements of the Registrant required to be filed with this 10-
QSB Quarterly Report were prepared by management, and commence on the
following page, together with Related Notes. In the opinion of management, the
Financial Statements fairly present the financial condition of the Registrant.

             CONDENSED CONSOLIDATED BALANCE SHEET


                          (unaudited)

                         June 30, 2005

 ASSETS
    Current Assets
          Cash                                $ 83,908
          Accounts Receivable                 $115,598
          Inventory                           $309,474
     Total Current Assets                     $508,980
     Fixed Assets
          Computer Equipment                  $ 40,337
          Equipment and Machinery             $ 42,858
          Furniture & Fixtures                $ 18,413
          Tooling                             $227,983
          Less Accumulated Depreciation      ($ 84,410)
     Total Fixed Assets                       $245,181
     Other Assets
          Deferred Patent Costs               $298,205
           Deposits                           $ 23,349
     Total Other Assets                       $321,554
TOTAL ASSETS                                $1,075,715
                                            ==========
LIABILITIES & STOCKHOLDERS' EQUITY
     Liabilities
          Current Liabilities
               Accounts Payable               $161,984
               Accrued Payroll                $265,029
               Accrued Vacation Pay           $ 32,446
               Warranty Accrual               $ 43,645
          Total Current Liabilities           $503,104
     Stockholders' Equity
          Common Stock                        $ 15,624
          Additional Paid in Capital        $4,711,457
          Deficit Accumulated during
            Development Stage              ($4,154,470)
     Total Stockholders' Equity               $572,611
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY    $1,075,715
                                            ==========

               CONDENSED STATEMENTS OF OPERATION


                          (unaudited)

                                 Three Months Ended      Six Months Ended
                                      June 30,               June 30,
                                 2005          2004      2005         2004
Revenues
     Sales                      $216,706   $ 118,547   $484,139   $ 259,692
     Services                          0           0      5,420           0
                                --------   ---------   --------   ---------
Total Revenues                   216,706     118,547    489,559     259,692
                                --------   ---------   --------   ---------
Cost of Goods Sold               114,832      61,515    248,591     140,485
                                --------   ---------   --------   ---------
Gross Profit                     101,874      57,032    240,968     119,207
                                --------   ---------   --------   ---------
Expenses
     Accounting & Audit            2,444       5,663     26,949      10,663
     Amortization Expense          8,542       7,411     14,837      18,742
     General Office Expenses       1,903       4,853      4,254       7,608
     Insurance                    13,366      10,125     32,298      20,459
     Legal Expenses                9,242       2,204     13,433       8,883
     Manufacturing & Production    3,772       6,587      7,519      15,692
     Marketing & Sales            17,683       9,477     41,295      25,141
     Office Equipment                795           0      2,729       3,748
     Office Supplies                 850       2,781      4,947       7,973
     Postage and Delivery          3,060       1,316      5,969       2,294
     Professional Fees             9,746           0     20,059           0
     Rent   Building              29,136       6,000     43,704      12,000
     Research & Development       22,495     148,662     32,803     265,015
     Salaries, Wages & Taxes     202,119     119,051    473,155     321,364
     Telephone & Utilities         4,485       3,890      9,853       7,580
     Property and State Taxes      1,236       1,288      1,237       1,285
                               ---------   ---------  ---------   ---------
Total Expenses                   330,874     329,308    735,041     728,447
                               ---------   ---------  ---------   ---------
Net Operating Loss              (229,000)   (272,276)  (494,073)   (609,240)
                               ---------   ---------  ---------   ---------
Net Other Income                   1,852         507      3,150       1,206
                               ---------   ---------  ---------   ---------
Net Loss Before Income Taxes    (227,148)   (271,769)  (490,923)   (608,034)
                               ---------   ---------  ---------   ---------
Current Year provision for
Income Taxes                           0           0          0           0
                               ---------   ---------  ---------   ---------
Net Loss                        (227,148)   (271,769)  (490,923)   (608,034)
                               =========   =========  =========   =========
Loss Per Share                    ($0.01)     ($0.03)    ($0.03)     ($0.06)
                               =========   =========  =========   =========
Average Shares Outstanding    15,624,188  10,255,070 15,564,575   9,666,425
                              ----------  ---------- ----------  ----------

        CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


                                (unaudited)

                                Three Months Ended        Six Months Ended
                                      June 30,               June 30,
                                 2005         2004       2005         2004

Cash Flows From Operating Activities
   Net Income (Loss)          $(227,148)  $(271,769)  $(490,923)    $(608,034)
   Adjustments of net income
   (loss) to net cash
   provided by operations:
      Amortization                2,380         307       2,604         1,229
      Depreciation                6,162       7,104      12,233        28,418
      (Increase) decrease in
      current assets             61,462     (21,534)     85,248       (13,852)
      Increase (decrease) in
      current liabilities        59,934      82,559      90,174       221,266
                              ---------   ---------  ----------    ----------
   Net cash provided (used) by
   operating activities         (97,210)   (203,333)   (300,664)     (370,973)
                              ---------   ---------  ----------    ----------

Cash Flows From Investing Activities
   Purchases of Fixed Assets     (1,098)    (32,119)     (1,098)      (47,526)
   (Increase) decrease in other
   assets                        (6,455)    (22,515)    (26,671)      (31,216)
                              ---------   ---------  ----------    ----------
   Net cash provided (used) by
   investing activities          (7,553)    (54,634)    (27,769)      (78,742)
                              ---------   ---------  ----------    ----------

Cash Flows from Financing
   Capital Stock Issued               0      82,242      10,583       338,243
                              ---------   ---------  ----------    ----------

Net Increase (Decrease)
   in cash                     (104,763)   (175,725)   (317,850)     (111,472)

Cash at beginning of period     188,671     339,445     401,758       275,192
                              ---------   ---------  ----------    ----------
Cash at end of period            83,908     163,720      83,908       163,720
                              =========   =========  ==========    ==========

Supplemental disclosure of cash flow
information
   Interest paid                      0           0           0             0
   Income taxes paid                800         800         800           800
   Item not affecting cash            0           0           0             0

                     See accompanying notes.

                           eGene, Inc.

      NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                         June 30, 2005

                          (Unaudited)

1. ORGANIZATION AND INTERIM FINANCIAL STATEMENTS

Effective July 13, 2004, Centroid Consolidated Mines Co., (Centroid), which
changed its name to eGene, Inc. (eGene), completed a merger with BioCal
Technology, Inc., (BioCal) a private California corporation in the business of
developing, manufacturing, and marketing genetic analyzer systems and reagents
for the global genetic testing market. In conjunction with our merger, we
raised $1.6 million in private funding. We had no material business operations
at the time that we acquired BioCal Technology.

The merger caused BioCal to become a wholly-owned subsidiary of eGene, a
dormant, publicly held Nevada corporation. The terms of the merger provided
that eGene exchange one of its shares of common stock for every three
outstanding shares of common stock of BioCal and one of its options to acquire
shares of common stock of eGene for every three outstanding options to acquire
common stock of BioCal. The combination was a "reverse merge". The transaction
was accounted for as a recapitalization of BioCal wherein the net assets are
brought forward at their net book value with no goodwill recognized, and the
pre-merger financial statements of BioCal became the historical financial
statements of the combined company.

The directors and executive officers of BioCal subsequently became the
directors and officers of the reorganized entity. Our Centroid Nevada
corporation has changed its name to eGene, Inc.

The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-QSB and
Article 10 of Regulation S-X of the Securities and Exchange Commission
("SEC"). Accordingly, they do not include all of the information and footnotes
required by accounting principles generally accepted in the United States for
complete financial statements. In the opinion of management, all adjustments
(consisting of normal recurring entries) considered necessary for a fair
presentation have been included. Operating results for the three and six
months ended June 30, 2005, are not necessarily indicative of the results that
may be expected for the full year ending December 31, 2005.  It is suggested
that these condensed consolidated financial statements be read in conjunction
with the consolidated financial statements and notes thereto included in the
Company's Annual Report for the year ended December 31, 2004.

Principles of Consolidation

eGene's financial statements include the accounts of its wholly owned
subsidiary BioCal Technology, Inc. All significant inter-company balances and
transactions have been eliminated in consolidation.

2.  UNREGISTERED SALES OF EQUITY SECURITIES

     The following stock options were exercised in the first quarter of 2005.

Udo Henseler                 1/31/2005             103,333 shares
Rolf Kojima                  2/16/2005              11,667 shares
Ming S. Liu                  3/16/2005              96,667 shares

          * These securities were sold under Rule 506 of Regulation D of the
            Securities and Exchange Commission and Section 4(2) of the
            Securities Act of 1933, as amended.  All purchasers were either
            "accredited investors" or directors, officers or affiliates of our
            Company.

3. STOCK-BASED COMPENSATION

     eGene accounts for its stock options and equity awards under the
intrinsic value method in accordance with the provisions of Accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees",
and related interpretations, and has elected to follow the "disclosure only"
alternative prescribed by Financial Accounting Standards Board's SFAS No. 123,
"Accounting for Stock-Based Compensation".  Accordingly, no compensation
expense is recognized in eGene's financial statements for stock options
granted to employees, which had an exercise price equal to the fair value of
the underlying common stock on date of grant.  eGene accounts for stock
options listed to non-employees in accordance with the provisions of SFAS No.
123 and EITF No. 96-18, "Accounting for Equity Instruments that are issued to
other than Employees for Acquiring or in Conjunction with selling Goods or
Services".

     The following table illustrates the effect on net loss and net loss per
share if eGene had applied the fair value recognition provisions of SFAS No.
123, as amended by SFAS No. 148, "Accounting for Stock-Based Compensation-
Transition and Disclsoure- and amendment of FASB Statement No. 123."  For
purposes of pro forma disclosures, the estimated fair value of the options is
amortized to expense over the vesting period of the options using the
straight-line allocation method.  eGene's pro forma information is as follows:

                       Three Months Ended June 30,   Six Months Ended June 30,
                            2005       2004              2005      2004
Net loss, as reported   $(227,148)  $(271,769)     $(490,923)     $(608,034)
 Compensation cost under
fair value-based
accounting method, net
of tax                      1,194          53          1,447            711
Net loss, pro forma      (228,342)   (271,822)      (492,370)      (608,745)

Net loss per common share
   Basic and Diluted
      As reported       $   (0.01)   $  (0.03)     $   (0.03)    $    (0.06)

      Pro forma             (0.01)      (0.03)         (0.03)         (0.06)

Weighted average shares 15,624,188  10,255,070     15,564,575      9,666,425

     The fair value under FAS 123 for options and equity awards granted were
estimated at the date of grant using a Black-Scholes option pricing model with
the following weighted average assumptions:

            Expected life (years)       5-8
            Interest rate                 3%
            Volatility                    0%
            Dividend yield                0%

4.  INVENTORIES

     Inventories are stated at the lower of cost or market.  Inventories at
June 30, 2005 consisted of the following:

                                                    June 30,
                                                      2005

           Finished goods                        $      43,500
           Work-in-process                                   0
           Raw materials                               265,974
                                                 -------------
           Total                                 $     309,474
                                                 =============

5.  SUBSEQUENT EVENTS

At a meeting held on July 19, 2005, the Board of Directors of eGene voted to
remove Dr. Udo Henseler as Chief Executive Officer (CEO) of the Company and to
replace him with Ming S. Liu, all effective as of that date. On July 20, 2005,
Jeffrey S. Williams resigned as Chief Financial Officer of eGene, effective as
of that date. As of the date of this 10-QSB Quarterly Report, we have not
filled the vacancy left by Mr. Williams' resignation.  The Company is
negotiating the final outcome of future payments to be made to the former CEO,
the outcome of which cannot be reasonably determined at this time.  As of June
30, 2005, the Company has accrued for all accrued wages and vacation due to
the former CEO, amounting to $111,790.

Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.

This Management's Discussion and Analysis of Financial Condition and Results
of Operations as of June 30, 2005, and for the three and six month period
ended June 30, 2005 and 2004, should be read in conjunction with our financial
statements included in our 10-KSB Annual Report for the year ended December
31, 2004, that was filed with the Securities and Exchange Commission on April
15, 2005 (the "2004 10-KSB Annual Report").

Statements made in this 10-QSB Quarterly Report which are not purely
historical are forward-looking statements with respect to our goals, plan
objectives, intentions, expectations, financial condition, results of
operations, future performance and business, including, without limitation,
(i) our ability to raise capital, and (ii) statements preceded by, followed by
or that include the words "may," "would," "could," "should," "expects,"
"projects," "anticipates," "believes," "estimates," "plans," "intends,"
"targets" or similar expressions. Forward-looking statements involve inherent
risks and uncertainties, and important factors (many of which are beyond our
Company's control) that could cause actual results to differ materially from
those set forth in the forward-looking statements, including the following,
general economic or industry conditions, nationally and/or in the communities
in which we conduct business, changes in the interest rate environment,
legislation or regulatory requirements, conditions of the securities markets,
our ability to raise capital, changes in accounting principles, policies or
guidelines, financial or political instability, acts of war or terrorism,
other economic, competitive, governmental, regulatory and technical factors
affecting our operations, products, services and prices.

Accordingly, results actually achieved may differ materially from expected
results in these statements. Forward-looking statements speak only as of the
date they are made. We do not undertake, and specifically disclaim, any
obligation to update any forward-looking statements to reflect events or
circumstances occurring after the date of such statements.

Executive Summary.

Business.

We are an emerging biotechnology company that utilizes the affordable
technologies of capillary electrophoresis, microfluidics, advanced reagents,
liquid handling and automation to create a cutting-edge genetic analyzer for
the biological materials and life sciences testing industries. Our objective
is to provide new, effective and superior biological testing tools and
information for improved customer decision-making and productivity. We deliver
applications and tools to these industries, which we believe will have
immediate commercial relevance. Our HDA-GT12 (High-Performance DNA and RNA
Analyzer) system detects, quantifies, identifies and characterizes biological
organisms. It advances and automates many routine and non-routine genetic
laboratory and industrial procedures that include, but are not limited to, new
and improved production methods, enhanced and novel product development
opportunities, quality control, security, genetic identity, paternity, crime,
bioterrorism, pathogen detection, drug monitoring, safety methods and overall
productivity.

We are developing three channels to distribute our complete system solutions
to customers: Distributing directly to customers, distributing indirectly
through our international network of distributors, and distributing through
our early and developing original equipment manufacturer ("OEM") channels. Our
OEM distribution channel is only in a  early stage of development, but is an
example of our distribution network activities because it enables us to extend
the commercial potential of our DNA HDA-GT12 system and advanced technologies
into new industries and new applications with experienced commercial partners.
In the OEM channel, we plan to provide our enabling technologies to potential
commercial partners who will then integrate the application solution and
market them to their end customers.

Critical Accounting Policies, Estimates and Assumptions.

We consider our accounting policies related to revenue recognition, inventory
reserve, and warranty accrual to be critical. Inherent in our determination of
when to recognize revenue, and in our calculation of our inventory reserve and
warranty accrual, are a number of significant estimates, assumptions and
judgments. These include deciding whether the elements required to recognize
revenue from a particular arrangement are present and estimating the amount of
inventory obsolescence and warranty costs associated with shipped products. We
base our estimates and judgments on historical experience and on various other
assumptions that we believe to be reasonable under the circumstances. Actual
results could differ materially from these estimates. There have been no
material changes to our critical accounting policies since we filed our 2004
Annual Report on Form 10-KSB with the Securities and Exchange Commission. For
a description of our critical accounting policies, please refer to our 2004
Annual Report on Form 10-KSB.

Second Quarter Overview.

During the second quarter of 2005, our sales increased $98,159, or 83%, from
sales of $118,547 in the second quarter of 2004. This increase in our
quarterly sales reflects our continued early product sales ramp up from our
acquisition of BioCal in July of 2004. The increase in sales reinforces our
confidence that we will achieve more appreciable growth in the future. We
expect our higher future sales to result in reduced operating losses and
improved operating cash flows.

Severe new equity funding delays are creating material commercial success
uncertainties for us. Our accompanying financial statements have been prepared
assuming we will continue as a going concern. However, as discussed in Note 2
to our audited financial statements of our year ended December 31, 2004, that
are contained in the 2004 10-KSB Annual Report, we have accumulated losses and
are still developing our planned principal operations. These factors and
ongoing delays in new funding raise substantial doubt about our ability to
continue as a going concern. Our financial statements do not include any
adjustments that might result from the outcome of this uncertainty.

We have limited financial resources and our operations from inception through
June 30, 2005, have been unprofitable. We are still commencing our planned
principal operations and seeking increased capital funding. If we are
unsuccessful in our efforts and cannot attain sufficient profitable operations
or if we cannot obtain additional sources of funding or investments, we may
substantially curtail or terminate our operations.

Results of Operations.

Revenue.

Total sales increased for the three months ended June 30, 2005, as compared to
the same period in 2004. Our sales increased 98,159, or 83% from sales of
$118,547 in the second quarter of 2004. This increase in our quarterly sales
reflects our continued early product sales ramp up from our acquisition of the
young, private company, BioCal in July of 2004. We believe this signifies that
we will be able to achieve more appreciable growth in the future. We expect
our higher future sales to result in reduced operating losses and improved
operating cash flows. We had no material business operations at the time that
we acquired BioCal.

                   Three Months Ended
                        June 30,

                    2005      2004      $change   %change 2004

Total Revenues     $216,706  $118,547    $98,159       83%


Cost of Sales.

In addition to our goal of attaining more sustainable revenue growth, we are
continuing to focus on improving our gross margins and controlling product
costs by seeking the benefits of cost effective global sourcing opportunities
in order to break even in our operating cash flow at lower overall revenues.

Expenses.

Total expenses for the quarter ended June 30, 2005, were $330,874, which was
$1,566 higher as compared to the same period in 2004.

The major expense levels and increases were for payroll, marketing and sales,
professional fees and legal expenses.

We expect to devote additional expense resources to continue our research and
development activities, substantially strengthening and broadening our
marketing and sales infrastructure, and for other general corporate
activities.

Selling and marketing expenses are expected to increase primarily due to
planned amplified sales that require augments in personnel costs related to
our initial and future growth related construction of our marketing, sales and
service functions, and general increases in other marketing and sales support
initiatives. We expect selling, marketing and product promotion expenses to
grow over the next several years to support a more global commercialization of
our products.

General and administrative expenses are expected to increase as a result of
more commercial activities and as a consequence of operating as a public
company subject to the many regularity demands. Certain general and
administrative expenses in the legal and insurance categories increased
primarily due our BioCal merger and related consequences. We anticipate that
general and administrative expenses will continue to increase.

The net loss for the quarter ended June 30, 2005, was $227,148, which was
$44,621 lower compared to the previous year's quarterly loss of $271,769.

Liquidity and Capital Resources.

Our cash and cash equivalents were $83,908 at June 30, 2005, compared to
$163,720 at June 30, 2004.

We have financed our operations primarily through equity sales and initial
product sales and services. The inclusion of BioCal operations after July 14,
2004, had a significant impact on our business and the comparability of cash
flows on a period-over-period basis.

Cash Flows.
-----------

                                   Three Months Ended
                                         June 30,
                                     2005       2004        $change

Net Cash provided (used)
by operating activities        $(97,210)     $(203,333)     $106,123

Cash Flows from
investing activities            $(7,553)      $(54,634)      $47,081

Cash Flows from
Financing activities                 $0        $82,242      $(82,242)

Operating Activities.

During the three months ended June 30, 2005, we used $97,210 of cash for
operating activities as compared to $203,333 of cash used in the same period
of 2004.

Investing Activities.

Investing activities during the three months ended June 30, 2005, were $1,098
for purchase of fixed assets and $6,455 for additional costs incurred for
deferred patent legal fees.

Financing Activities.

During the three months ended June 30, 2005, expected new funding activities
from the sale of our common stock and options in various private placements
did not materialize.

The material new equity funding delays are creating severe commercial success
uncertainties for us. Our accompanying financial statements have been prepared
assuming we will continue as a going concern. As discussed in Note 2 to our
audited financial statements of our year ended 2004 that are contained in our
2004 10-KSB Annual Report, we have accumulated losses and are still developing
our planned principal operations. These factors and ongoing delays in new
funding raise substantial doubt about our ability to continue as a going
concern. Our financial statements do not include any adjustments that might
result from the outcome of this uncertainty.

We have limited financial resources and our operations through June 30, 2005,
have been unprofitable. We are still commencing our planned principal
operations and seeking increased capital funding. If we are unsuccessful in
our efforts and cannot attain sufficient profitable operations or if we cannot
obtain additional sources of funding or investments, we may substantially
curtail or terminate our operations.

If, however, our current in-progress private placement of "restricted
securities" to "accredited investors" only is successful and we achieve the
revenues to be derived from our commercial sales of our products, our cash
balances will be sufficient to fund our operations at least through 2005. If
we are unsuccessful in our efforts to obtain additional sources of funding or
investments, we may substantially curtail or terminate our operations.

Our future capital requirements will depend on many factors, including, among
others:

* continued market acceptance of our genotyping products;

* continued scientific progress in product development programs;

* the magnitude and scope of our research and product development programs;

* our ability to maintain and establish additional, partnerships and licensing
arrangements;

* the time and costs involved in expanding and maintaining our manufacturing
facilities;

* the costs involved in preparing, filing, prosecuting, maintaining, defending
and enforcing patent claims;

* the potential need to develop, acquire or license new technologies and
products; and

* other factors not within our control.

Our actual cash needs could vary considerably depending upon how successful we
are in our efforts to obtain additional sources of funding or investments,
opportunities and commercial uncertainties that may arise over the course of
the remaining period of 2005 and the full year 2006. During or after this
period, if cash generated by operations is insufficient to satisfy our
liquidity requirements, we may need to sell additional equity or debt
securities or obtain additional credit arrangements. An inability to obtain
additional financing may force delays in research and product development
activities and, ultimately, cause us to cease operations.

In the future, we may seek additional funds to support our strategic business
needs and may seek to raise such additional funds through private or public
sales of securities, strategic relationships, bank debt, lease financing
arrangements or other available means. If additional funds are raised through
the issuance of equity or equity-related securities, stockholders may
experience additional dilution, or such equity securities may have rights,
preferences or privileges senior to those of the holders of our common stock.
If adequate funds are not available or are not available on acceptable terms
to meet our business needs, our business may be harmed.

Going Concern Qualification of our Auditors.

Our accompanying financial statements have been prepared assuming we will
continue as a going concern. We have accumulated losses and are still
developing our planned principal operations. These factors raise substantial
doubt about our ability to continue as a going concern. Management's plans in
regard to these matters are also described in Note 2 of our audited financial
statements that are contained in our 2004 10-KSB Annual Report. These
financial statements do not include any adjustments that might result from the
outcome of this uncertainty.

Risk Factors Affecting Operating Results.

The following risk factors should be considered, among others, in evaluating
eGene's business, products and prospects. This list is not inclusive.

Risks Related to Our Business.

Our Genetic Analyzer Products May Not Achieve Market Acceptance, Which Could
Cause Revenue to Grow Slowly or Decline.

Our genetic analyzer products, which we developed, are still in relatively
early stages of their technology life cycle and have only recently begun to be
used commercially. If these systems do not gain further market acceptance,
eGene will be unable to generate significant sales of these products and our
revenue may grow more slowly than expected or decline. The commercial success
of our genetic analyzer products will depend upon capital spending by our
potential customers, market acceptance of the merits of our genetic analyzer
capillary electrophoresis systems by biotechnology companies, academic
research centers and other companies that rely upon genotyping analyses.
Market acceptance will depend on many factors, including:

* our ability to demonstrate the advantages and potential economic value of
our genetic systems over alternative well-established technologies;

* capital spending by our customers and potential customers, which has been
sluggish as a result of current economic conditions and other industry-
specific factors; and

* our ability to market our genetic analyzer systems.

Because the genotyping capillary electrophoresis systems have been in
operation for only a limited period of time, their accuracy, reliability, ease
of use and commercial value have not been fully established. If early
customers do not endorse our genotyping systems because these systems fail to
generate the quantities and quality of data they expect, are too difficult or
costly to use or are otherwise deficient, market acceptance would suffer and
further sales may be limited. We cannot assure you that these customers'
efforts to put our high throughput systems into use will continue or will be
expeditious or effective. Potential customers for these systems may also wait
for indications from eGene's early genetic system customers that our system
works effectively and generate substantial benefits. Further, non-acceptance
by the market of our initial systems could undermine not only those systems
but subsequent systems as well.

The genetic analyzer productivity tools equipment market is competitive and is
characterized by technological change and frequent new product introductions.
The commercial success of our genetic systems depends upon continued and
expanding market acceptance of our systems and products by biotechnology
companies and genomics research organizations, and upon availability to
address quickly any performance problems that our customers encounter. We
anticipate that our competitors will introduce new, enhanced products in this
market. Our future success will depend on our ability to offer new products
and technologies that researchers believe are an attractive alternative to
current products and technologies that address the evolving needs of our
customers and that are technologically superior to new products that may be
offered by competitors. We may experience difficulties or delays in the
development efforts for new products, and we may not ultimately be successful
in developing them. Any significant delay in releasing new products in this
market could adversely affect us or our reputation, give a competitor a first-
to-market advantage or cause a competitor to achieve greater market share.

We intend to continue developing new, lower cost versions of our genetic
analyzer systems with enhanced features that address existing or emerging
customer needs, such as novel assay functionalities. If we are unable to do
so, our systems may not become more widely used and we may experience a
decline in revenue or slow revenue growth and may not achieve or maintain
profitability.

Our Sales Cycle Can Be Lengthy, Which Can Cause Variability and
Unpredictability In Our operating Results.

The sales cycles for our products, particularly in the genetic/life sciences
market, can be lengthy, which makes it more difficult for us to forecast
revenues in a given period, and may cause revenues and operating results to
vary significantly from period to period. Sales of our product to the life
sciences market often involves purchasing decisions by large public and
private institutions, and any purchases can require many levels of pre-
approval. In addition, many of these sales depend on these institutions
receiving research grants from various federal agencies, which grants vary
considerably from year to year in both in amount and timing due to the
political process. As a result, we may expend considerable resources on
unsuccessful sales efforts or we may not be able to complete transactions on
the schedule anticipated.

eGene's Business May Be Adversely Affected By Downturns In The Economy.

We are subject to the capital spending patterns of this industry, which over
the past several years have been unfavorably impacted by general economic
conditions and increased competition. If our customers and potential customers
do not increase their capital spending budgets, eGene could face weak demand
for our products.

eGene's Industry Is Very Competitive.

Our business is highly competitive and our growth is dependent upon market
growth and our ability to enhance our existing products and introduce new
products on a timely basis. One of the ways we may address the need to develop
new products is through acquisitions of complementary businesses and
technologies. Acquisitions involve numerous risks.

eGene Has Not Recorded Profitable Operations Since Its Inception And May Never
Achieve Profitability.

We expect to incur future operating losses and may not achieve profitability.
We have experienced development stage operating losses each year since 1999
and expect to incur additional operating losses for the calendar year of 2005,
primarily as a result of a current slow economic climate, and expected
continuing expenses for manufacturing capabilities, research and product
development costs and general and administrative costs. We may never achieve
profitability.

Our operating results may fluctuate significantly and any failure to meet
financial expectations may disappoint securities analysts or investors and
result in a decline in its stock price.

eGene Has Limited Manufacturing Experience.

We have limited experience in manufacturing of our products and may encounter
manufacturing problems or delays, which could result in lost revenue.

eGene Depends On Its Key Personnel, The Loss Of Whom Would Impair Its Ability
to Compete.

We are highly dependent on the principal members of our management (Dr. Ming
Liu and Varouj Amirkhanian). The loss of services of any of these persons
could seriously harm product development, commercialization efforts and
business success. In addition, research, product development and
commercialization will require additional skilled personnel in areas such as
chemistry and biology, software engineering and electronic engineering.
Competition for and retention of personnel, particularly for employees with
technical expertise, is intense and the turnover rate for these people is
high. If we are unable to hire, train and retain a sufficient number of
qualified employees, our ability to conduct and expand our business could be
reduced. The inability to retain and hire qualified personnel could also
hinder the planned expansion of our business.

At a meeting held on July 19, 2005, the Board of Directors of eGene voted to
remove Dr. Udo Henseler as Chief Executive Officer of the Company and to
replace him with Ming S. Liu, all effective as of that date. On July 20, 2005,
Jeffrey S. Williams resigned as Chief Financial Officer of eGene, effective as
of that date. As of the date of this 10-QSB Quarterly Report, we have not
filled the vacancy left by Mr. Williams' resignation. Please read in
conjunction with our 8-K Current Report dated July 19, 2005 filed with
Securities and Exchange Commission on July 25, 2005.

eGene's Intellectual Property Rights May Not Protect It And Its Products.

Our products could infringe on the intellectual property rights of others,
which may cause us to engage in costly litigation and, if we are not
successful, could also cause us to pay substantial damages and prohibit us
from selling our products. Third parties may assert infringement or other
intellectual property claims against us. Even if these claims are without
merit, defending a lawsuit takes significant time, may be expensive and may
divert management attention from other business concerns. We are not aware of
any third-party patents claims against us.

We may need to initiate lawsuits to protect or enforce our patents, which
would be expensive and, if we lose, may cause us to lose some of our
intellectual property rights, which would reduce our ability to compete in the
market. We rely on patents to protect our intellectual property and our
competitive position, especially in our capillary electrophoresis
microfluidics business. The rights eGene relies upon to protect our
intellectual property underlying company products may not be adequate, which
could enable third parties to use this technology and would reduce our ability
to compete in the market.

In addition to patents, we rely on a combination of trade secrets, copyright
and trademark laws, nondisclosure agreements and other contractual provisions
and technical measures to protect our intellectual property rights.
Nevertheless, these measures may not be adequate to safeguard the technology
underlying company products.

Notwithstanding our efforts to protect our intellectual property, our
competitors may independently develop similar or alternative technologies or
products that are equal or superior to company technology and products without
infringing on any of our intellectual property rights or design around company
proprietary technologies.

The Loss of One or More Suppliers of eGene May Have an Adverse Effect on its
Operations.

We obtain some of the components and subassemblies included in our systems
from a single source or a limited group of suppliers, and the partial or
complete loss of one of these suppliers could cause production delays and a
substantial loss of revenue.

We maintain only a limited number of long-term supply agreements with its
suppliers.

Our reliance on a limited group of suppliers involves several risks, including
the following:

* we may be unable to obtain an adequate supply of required components;

* we have reduced control over pricing and the timely delivery of components
and subassemblies; and

* company suppliers may be unable to develop technologically advanced products
to support our growth and development of new systems.

Because the manufacturing of certain of these components and subassemblies
involves complex processes and requires long lead times, we may experience
delays or shortages caused by suppliers. We believe that alternative sources
could be obtained at the same prices and on substantially the same terms and
conditions, if necessary, for most sole and limited source parts. However, if
we were forced to seek alternative sources of supply or to manufacture such
components or subassemblies internally, we might be forced to redesign company
systems, which could prevent us from shipping our systems to customers on a
timely basis.

eGene May Need Additional Capital.

Failure to raise additional capital or generate the significant capital
necessary to expand our operations and invest in new products could reduce our
ability to compete and result in lower revenue. We anticipate that our
existing capital resources and in progress private placement will enable us to
maintain currently planned operations at least through year 2005. However, we
premise this expectation on our current successful private placement, which is
lagging significantly in terms of cash in-flow so far. We may need additional
funding sooner than anticipated. Our inability to raise needed capital would
harm our business. In addition, we may choose to raise additional capital due
to market conditions or strategic considerations even if we believe we have
sufficient funds for our current operating plans. To the extent that
additional capital is raised through the sale of equity or convertible debt
securities, the issuance of these securities could result in dilution to our
stockholders.

We currently have no credit facility or committed sources of capital. To the
extent operating and capital resources are insufficient to meet future
requirements, we will have to raise additional funds to continue the
development and commercialization of our technologies. These funds may not be
available on favorable terms, or at all. If adequate funds are not available
on attractive terms, we may be required to curtail operations significantly or
to obtain funds by entering into financing, supply or collaboration agreements
on unattractive terms

Risks Related to Owning Our Common Stock.

Our shares of common stock are traded on the OTC Bulletin Board under the
symbol "EGEI"; however, there is not and has not been any "established trading
market" for these securities. Our stock price has very little history, and you
could lose a substantial portion of your investment.

Our stock has been trading on the OTCBB only since October 2004. We initially
offered our common stock to the public at $1.00 per share in a private
placement to "accredited investors" only. We expect that our stock price will
remain volatile as a result of a number of factors, including:

* announcements by our competitors of complementary or competing products and
technologies;

* announcements of our financial results, particularly if they differ from
investors' expectations; and

* general market volatility for technology stocks.

These factors and fluctuations, as well as general economic, political and
market conditions, may materially adversely affect the market price of our
common stock.

We are at risk of future securities class action litigation.

Given the newness of our stock, we are at risk of having securities class
action lawsuits filed against us and our officers and directors. Such
securities litigation could result in potential liability, cause us to incur
litigation costs and divert management's attention and resources, any of which
could harm our business. In addition, announcements of lawsuits of this or
some other nature, and announcements of events occurring during the course of
the lawsuits, could cause our stock fall.

Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Sensitivity.

Our primary investment objective is to preserve principal while at the same
time maximizing yields without significantly increasing risk. Our portfolio
includes money markets funds.

Item 3. Controls and Procedures.

We have evaluated our "disclosure controls and procedures" and our "internal
controls and procedures for financial reporting" as of June 30, 2005. This
evaluation was done under the supervision and with the participation of
management.

Evaluation of Disclosure Controls and Procedures.

Regulations under the Securities Exchange Act of 1934 require public
companies, including our company, to evaluate any change in our "internal
control over financial reporting," which is defined as a process to provide
reasonable assurance regarding the reliability of financial reporting and
preparation of financial statements for external purposes in accordance with
accounting principles generally accepted in the United States. In connection
with our evaluation of our disclosure controls and procedures as of the end of
the period covered by this Quarterly Report, our Chief Executive Officer,
Executive Vps and Business Manager did not identify any change in our internal
control over financial reporting during the three months ended June 30, 2005
that materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting. Disclosure controls are designed
with the objective of ensuring that information is accumulated and
communicated to our management, as appropriate to allow timely decisions
regarding required disclosure. It should be noted though that eGene is a young
and emerging biotechnology company with limited resources, funding and
personnel, and that our evaluation of controls and procedures were conducted
in good faith considering the economic environment of our Company.

Changes in Internal Controls.

Internal controls over financial reporting are procedures which are designed
with the objective of providing reasonable assurance that: (1) our
transactions are properly authorized; (2) our assets are safeguarded against
unauthorized or improper use; and (3) our transactions are properly recorded
and reported, all to permit the preparation of our financial statements in
conformity with accounting principles generally accepted in the United States.
Among other matters, we evaluated our internal controls over financial
reporting to determine whether there were any "significant deficiencies" or
"material weaknesses," and sought to determine whether we have identified any
acts of fraud involving personnel who have a significant role in eGene's
internal controls. In the professional auditing literature, "significant
deficiencies" may be interpreted as being comparable as "reportable
conditions"; these are control issues that could have a significant adverse
effect on the ability to record, process, summarize, and report financial data
in the financial statements. A "material weakness" is defined in the auditing
literature as a particularly serious reportable condition where the internal
control does not reduce to a relatively low level the risk that misstatements
caused by error or fraud may occur in amounts that would be material in
relation to the financial statements and would not be detected within a timely
period by employees in the normal course of performing their assigned
functions.

There were no material changes in our internal controls over financial
reporting during the quarter ended June 30, 2005, that have materially
affected, or are reasonably likely to materially affect, our internal control
over financial reporting.

Consistent with Section 10A(i)(2) of the Securities Exchange Act of 1934, as
added by Section 202 of the Sarbanes-Oxley Act of 2003, we are responsible for
listing the non-audit services approved by our Chief Executive Officer to be
performed by Mantyla McReynolds LLC, our independent auditor. Non-audit
services are defined as services other than those provided in connection with
an audit or a review of our financial statements.

Limitations on the Effectiveness of Controls.

Our management does not expect that our disclosure controls or our internal
controls will prevent all error and all fraud. A control system can provide
only reasonable, not absolute, assurance that the objectives of the control
system are met. Further, the design of a control system must reflect the fact
that there are resource constraints, and the benefits of controls must be
considered relative to their costs. Because of the inherent limitations in all
control systems, no evaluation of controls can provide absolute assurance that
all control issues and instances of fraud, if any, within our Company have
been detected. These inherent limitations include the realities that judgments
in decision-making can be faulty, and that breakdowns can occur because of
simple error or mistake. Additionally, controls can be circumvented by the
individual acts of some persons, by collusion of two or more people or by
management override of the control. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur
and not be detected.

                   Part II Other Information

Item 1. Legal Proceedings.

None; not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None; not applicable.

Item 3. Defaults Upon Senior Securities.

None; not applicable.

Item 4. Submission of Matters to a Vote of Security Holders.

None; not applicable.

Item 5. Other Information.

At a meeting held on July 19, 2005, the Board of Directors of eGene voted to
remove Dr. Udo Henseler as Chief Executive Officer (CEO) of the Company and to
replace him with Ming S. Liu, all effective as of that date. On July 20, 2005,
Jeffrey S. Williams resigned as Chief Financial Officer of eGene, effective as
of that date. As of the date of this 10-QSB Quarterly Report, we have not
filled the vacancy left by Mr. Williams' resignation.  The Company is
negotiating the final outcome of future payments to be made to the former CEO,
the outcome of which cannot be reasonably determined at this time.  As of June
30, 2005, the Company has accrued for all accrued wages and vacation due to
the former CEO, amounting to $111,790.

Item 6. Exhibits.

Exhibits:

31.1 302 Certification of Ming S. Liu

32 906 Certification


                          SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Quarterly Report to be signed on its behalf by
the undersigned, thereunto duly authorized.

                                eGene, Inc.



Dated: August 11, 2005          By:  /s/ Ming S. Liu
                                Ming S. Liu
                                Chief Executive Officer, Executive
                                Vice President and Director